| Lin Shen,Qing Wei. Implications of the mismatch repair-deficient status for the management of colorectal cancers. Oncol Transl Med, 2017, 3: 20-24. |
| Implications of the mismatch repair-deficient status for the management of colorectal cancers |
| Received:August 26, 2016 Revised:February 15, 2017 |
| View Full Text View/Add Comment Download reader |
| KeyWord:colorectal cancer (CRC); mismatch repair; microsatellite instability; immunotherapy |
| Author Name | Affiliation | E-mail | | Lin Shen | Department of Gastrointestinal Oncology,Key laboratory of Carcinogenesis and Translational Research Ministry of Education,Peking University Cancer Hospital Institute,Beijing,China | lin100@medmail.com.cn | | Qing Wei | Department of Gastrointestinal Oncology,Key laboratory of Carcinogenesis and Translational Research Ministry of Education,Peking University Cancer Hospital Institute,Beijing,China
Department of Gastrointestinal Oncology,Key laboratory of Carcinogenesis and Translational Research Ministry of Education,Peking University Cancer Hospital Institute,Beijing,China | weiqingmd@163.com |
|
| Hits: 7944 |
| Download times: 9397 |
| Abstract: |
| Although the majority of colorectal cancer (CRC) cases develop through the CIN pathway, approximately 15%
of cases are caused by the hypermutation known as microsatellite instability (MSI) that is a consequence of
deficient (d) DNA mismatch repair (MMR). dMMR CRCs have distinct phenotypic characteristics compared
with microsatellite stable (MSS) tumors. MSI CRC is associated with an earlier stage at diagnosis and
improved stage-specific prognosis, although this is controversial in stage IV patients. Current evidence
supports the use of adjuvant chemotherapy with fluoropyrimidine plus oxaliplatin for stage III dMMR CRC.
The distinctive genomic characterization and expression profiling of dMMR CRC paves the way for tailored
immunotherapies. This is supported by recent studies that highlighted the efficacy of immunotherapy in
dMMR CRC. Here, we describe the molecular aspects of the MMR system and discuss the associations of
MMR-deficient/MSI-H status with clinical management, especially for patients with metastatic CRC. |
| Close |
|
|
|